Announcements Trials

Browse Landscape

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 92 Observational 5 Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 2 Squamous Non-Small Cell Lung Cancer 1 Neoplasms 1

Interventions

Crizotinib 2 Bone Marrow Transplantation 2 3-Iodobenzylguanidine 2 vorasidenib 1 tucatinib 1 tovorafenib 1 tazemetostat 1 taletrectinib 1 olaparib 1 nirogacestat 1 glucarpidase 1 enzalutamide 1 denileukin diftitox 1 copanlisib 1 balstilimab 1 atezolizumab 1 adagrasib 1 Proton Pump Inhibitors 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 LY3023414 1 Hydrocortisone 1 Carboxypeptidases 1 Antibodies, Bispecific 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Neoplasms × Nivolumab × Clear all

NCT03126643 2021-11-29

Expanded Access to Nivolumab (Opdivo)

Bristol-Myers Squibb

Approved for marketing

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡